

PATH822 – Experimental Cancer Therapeutics (Fall 2013)

COURSE OUTLINE

Co-ordinator: Christopher J. Nicol (e-mail: nicolc@queensu.ca) (ext. 36531)

Days/Time: **Fridays - 9:30 am - 12:30 pm**

Location: Cancer Research Institute conference rooms 100/101 (ground floor)

Date	Session Leader(s)	Session Title	Student Presentations
Sept. 13	C. Nicol	Overview and Introduction to New Drug Development (<i>no presentations</i>)	None
Sept. 20	S. Davey	Molecular basis of oncogenic transformation & signalling pathways (<i>no presentations</i>)	None
Sept. 27*	C. Nicol	Challenges with Current Cancer Therapeutics	TBD
Oct. 4*	H. Feilotter	Molecular Evaluation of Tumours	TBD
Oct. 11*	G. Jones	Drug Discovery I - (small molecules)	TBD
Oct. 18*	C. Nicol	Experimental Drug Delivery (nanoparticles)	TBD
Oct. 25 *	V. Tron	Drug Discovery II - (non-small molecules, ie RNAi, DNA vaccines, gene therapy, viruses, etc)	TBD
Nov. 1*	J. Schreiner	Novel Imaging (increasing sensitivity for: preclinical testing; selecting responsive patients; molecular imaging agents for ultrasound, PET, CT, fMRI)	TBD
Nov. 8 *	P. Greer	Preclinical (in vitro and animal) Models for Validating Experimental Targets	TBD
Nov. 15 *	L. Shepherd / W. Parulekar	Cancer Chemotherapy & Clinical Drug Development	TBD
Nov. 22 *	M. Koti	Molecular Basis of Variability in Tumour Responses	TBD
Nov. 29 *	E. Eisenhauer	Clinical Results of Targeted Therapy	TBD
Dec. 6	Multiple TBD	Student Oral Grant Defenses	Schedule TBD

* Student presentations *will* be made on this day; **TBD**, To be determined.

PATH822 – Experimental Cancer Therapeutics (Fall 2013)

STUDENT RESEARCH GRANT PROPOSAL TOPICS

Students will choose a session topic for which they will select a grant topic (max. 2 per session). NOTE: Students should not choose a grant topic in your own research area or in a session in which you presented. Prior to writing, students should prepare an brief summary outline of their intended grant proposal, and arrange a meeting by e-mail or phone (see below) with the Session Leader to confirm the subject is appropriate.

RESEARCH PROPOSALS ARE DUE MON 11TH NOVEMBER @9:30AM
(a 5% mark deduction will be applied for each day late)

Session Leader(s)	Session Title	Student Grant Proposals
C. Nicol	Challenges with Current Cancer Therapeutics	TBD
H. Feilotter	Molecular Evaluation of Tumours	TBD
G. Jones	Drug Discovery-I (small molecules)	TBD
C. Nicol	Experimental Drug Delivery	TBD
V. Tron	Drug Discovery-II (non small molecules)	TBD
J. Schreiner	Novel Imaging	TBD
P. Greer	Preclinical (in vitro and animal) Models for Validating Experimental Targets	TBD
L. Shepherd & W. Parulekar	Cancer Chemotherapy & Clinical Drug Development	TBD
M. Koti	Molecular Basis of Variability in Tumour Responses	TBD
E. Eisenhauer	Clinical Results of Targeted Therapy	TBD

EVALUATION: Oral Presentation: 30%; Written Grant Proposal 40%; Student Participation 10%; Oral Grant Defense 20% (20 min per student)

PATH822 – Experimental Cancer Therapeutics (Fall 2013)

Session Leader Contact Information:

Name	Email	Queen's Ext.
Davey, Scott K.	scott.davey@queensu.ca	36923
Eisenhauer, Elizabeth A.	EEisenhauer@ctg.queensu.ca	36430/77716
Feilotter, Harriet E.	hf4@queensu.ca	81-1302
Greer, Peter A.	greerp@queensu.ca	32813
Jones, Glenville	gj1@queensu.ca	32494
Koti, Madhuri	kotim@queensu.ca	79055
Nicol, Christopher J.	nicolc@queensu.ca	36531
Parulekar, Wendy R.	WParulekar@ctg.queensu.ca	77745
Schreiner, John	John.Schreiner@krcc.on.ca	78510
Shepherd, Lois E.	LShepherd@ctg.queensu.ca	36430/77714
Tron, Victor	tronv@queensu.ca	79616